AML with Recurrent Genetic Abnormalities

AML with Recurrent Genetic Abnormalities — Trials · CancerIndex

Clinical trials

Registered studies

183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (35)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01869803	Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia	approved for marketing	—	—	Wake Forest University Health SciencesOTHER	1	Mar 2, 2018	clinicaltrials

Data updated 22 days agoSource updated Mar 2, 2018source: clinicaltrials